Bayer (BAYN) Given a €89.00 Price Target by Sanford C. Bernstein Analysts
Bayer (FRA:BAYN) has been given a €89.00 ($103.49) price target by equities researchers at Sanford C. Bernstein in a research note issued on Tuesday, Borsen Zeitung reports. The firm currently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s price objective points to a potential upside of 57.66% from the company’s current price.
A number of other equities research analysts also recently issued reports on the company. JPMorgan Chase & Co. set a €70.00 ($81.40) price objective on Bayer and gave the stock a “neutral” rating in a research report on Tuesday. Warburg Research set a €61.00 ($70.93) price objective on Bayer and gave the stock a “neutral” rating in a research report on Wednesday, May 1st. Baader Bank set a €123.00 ($143.02) price objective on Bayer and gave the stock a “buy” rating in a research report on Monday, April 29th. Goldman Sachs Group set a €77.00 ($89.53) price objective on Bayer and gave the stock a “buy” rating in a research report on Monday, April 29th. Finally, Barclays set a €85.00 ($98.84) price objective on Bayer and gave the stock a “buy” rating in a research report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of €81.67 ($94.97).
FRA:BAYN opened at €56.45 ($65.64) on Tuesday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
See Also: What is Green Investing?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.